Scaling up innovation in cardiovascular health
EU-wide support measure for the coordination and dissemination of research results and innovations in the field of cardiovascular health. Applications possible until 16.04.2026.
Discover your potential with AI support
- Find out if this grant matches your project
- Develop your application together with AI
- Get matched with many more suitable grants
Grant criteria
Funding objective
Support for coordination and accompanying measures to develop a strategic research and innovation roadmap for cardiovascular diseases (CVDs) in Europe, aimed at improving prevention, early detection, and personalized treatment approaches, and strengthening collaboration between research, healthcare, and policy.
Eligible expenses
- Personnel costs
- Travel and accommodation expenses
- Material costs (office supplies, publication costs)
- Consulting fees
- Event costs (workshops, conferences)
Non-eligible expenses
- Acquisition of real estate
- Retroactive costs
- Funding of clinical trials with pharmaceuticals
Eligible to apply
- Companies
- Non-profit Organizations
- Educational Institutions
- Public Institutions
Funding requirements
- Legal entity in an EU Member State or associated country
- Coordinator must be established in the EU or an associated country
- Existing Gender Equality Plan
- Registration and validation in the Participant Register
- Exclusion of sanctioned or financially non-viable entities
Documents required for application
- Project description (Part B)
- Financial plan with budget tables
- Curricula vitae of key personnel
- Consortium Agreement
Evaluation criteria
- Innovative content of the project
- Contribution to achieving objectives in the field of cardiovascular research
- Quality and efficiency of project implementation
Description
Scaling up Innovation in Cardiovascular Health is an EU-wide funding initiative that finances coordination and support activities in the field of cardiovascular research. The goal is to develop a Strategic Research and Innovation Agenda (SRIA) for the prevention, early detection, and personalized treatment of cardiovascular diseases (CVDs). With a funding amount of up to €1,900,000 and a funding rate of 100%, the Horizon Europe program supports companies, non-profit organizations, educational institutions, and public bodies from EU Member States and associated countries over a period of 36 months. Eligible costs include personnel expenses, travel costs, material costs, consultancy fees, and event expenses. Explicitly excluded are retrospective costs, real estate purchases, and the financing of clinical drug trials. Applications can be submitted until April 16, 2026, and are evaluated through a single-stage procedure. Key evaluation criteria are the degree of innovation, contribution to achieving objectives in the field of CVD research, as well as the quality and efficiency of project implementation.
The initiative targets researchers, policymakers, healthcare stakeholders, and technology developers who work closely with patient organizations. It funds cooperation and dissemination strategies to tailor research results to target groups and make them accessible to healthcare professionals. Gender equality plans as well as registration in the EU Participant Register are required. Sanctioned or financially non-viable entities are excluded. Participants are encouraged to share research outcomes within the EU context, leverage synergies with EU programs such as EU4Health, and develop IP strategies that consider open science principles and exploitation obligations. The aim is to strengthen collaboration between research, healthcare, and policy to sustainably reduce cardiovascular diseases in Europe.